Evidence map›Paper›PMID 40627802›Full record

ArticlePloS one2025

A longitudinal assessment of the antibody response to SARS-CoV-2 infection in the New Mexican population.

Frances M Twohig, Tonilynn M Baranowski, Chunyan Ye, Michelle Harkins, Steven B Bradfute

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Frances M TwohigDepartment of Internal Medicine, Center for Global Health, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America.
Tonilynn M BaranowskiDepartment of Internal Medicine, Center for Global Health, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America.
Chunyan YeDepartment of Internal Medicine, Center for Global Health, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America.
Michelle HarkinsDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America.
Steven B BradfuteDepartment of Internal Medicine, Center for Global Health, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America.ORCID https://orcid.org/0000-0002-1985-751X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While many studies have assessed immune responses to SARS-CoV-2 infection, none have studied functional antibody responses before and after vaccination of exposed patients in New Mexico in the United States. Here, we evaluate antibody binding, antibody neutralization, and antibody dependent cell-mediated cytotoxicity (ADCC) responses from convalescent patients between September 2020 and April 2021. Our results indicate that binding, neutralizing, and ADCC titers remained durable over an estimated 4-month period or were boosted by vaccination. Antibody binding titer stability was comparable to that of antibodies against four common viruses. Hispanic and Latino responses were similar to non-Hispanic/Latino responses in this cohort. Overall, these data shed light on functional antibody responses to SARS-CoV-2 in pre-alpha variant waves in New Mexico.

Indexed as

Antibodies, ViralAntibody FormationCOVID-19SARS-CoV-2AdultAntibodies, NeutralizingAntibody-Dependent Cell CytotoxicityFemaleHumansLongitudinal StudiesMaleMiddle AgedNew MexicoAntibodies, NeutralizingAntibodies, Viral

Identifiers

PMID40627802
PMCPMC12237266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.